Fidaxomicin was shown to be as good as the current standard-of-care, vancomycin, for treating CDI in a Phase III trial published in February 2011.<ref>{{cite journal |doi=10.1056/NEJMoa0910812 |title=Fidaxomicin versus vancomycin for Clostridium difficile infection |year=2011 |last1=Louie |first1=Thomas J. |last2=Miller |first2=Mark A. |last3=Mullane |first3=Kathleen M. |last4=Weiss |first4=Karl |last5=Lentnek |first5=Arnold |last6=Golan |first6=Yoav |last7=Gorbach |first7=Sherwood |last8=Sears |first8=Pamela |last9=Shue |first9=Youe-Kong |last10=Opt-80-003 Clinical Study |first10=Group |journal=New England Journal of Medicine |volume=364 |issue=5 |pages=422â€“31 |pmid=21288078}}</ref> The authors also reported significantly fewer recurrences of infection, a frequent problem with ''C. difficile'', and similar drug side effects.
